Abstract: A film comprising, consisting of, or consisting essentially of: a) a polyolefin component; b) an additive comprising i) a first polyethylene oxide/polyethylene copolymer having a HLB value in the range of from 1 to 7 and a structure selected from the group consisting of CH3CH2(CH2CH2)aCH2CH2(OCH2CH2)bOH and CH3CH2(CH2CH2)aCO(OCH2CH2)bOH wherein a is from 9 to 25 and b is from 1 to 10; and ii) a second polyethylene oxide/polyethylene copolymer having a HLB value in the range of from 7 to 18 and a structure selected from the group consisting of CH3CH2(CH2CH2)aCH2CH2(OCH2CH2)bOH and CH3CH2(CH2CH2)aCO(OCH2CH2)bOH wherein a is from 9 to 25 and b is from 1 to 10, is disclosed. The film is used in greenhouse applications.

Abstract: A colorant catcher material includes a) a substrate and b) a colorant-catching additive. The colorant-catching additive is selected from the group consisting of polyvinylamines in form of homopolymers, copolymers and/or partial salts thereof, polyethylenimines in form of homopolymers, copolymers and/or partial salts thereof, and mixture thereof. The colorant-catching additive is fixed on the substrate by c) a fixing agent selected from the group consisting of dialdehydes with the carbon number of from 2 to 8. Also disclosed is a method for preparing the colorant catcher material and use of the same for catching colorants or removing dirt in an aqueous medium, particularly a laundry washing solution.

Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.

Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.

Abstract: A multi-layer film comprising: a) a first layer comprising i) a polyolefin component; and ii) a polyethylene oxide/polyethylene copolymer having a Hydrophile-Lipophile Balance value in the range of from 2 to 6; b) a second layer comprising i) a polyolefin component; ii) from 1 to 5 weight percent of an additive selected from the group consisting of sorbitan esters, polyoxyethylene esters, glycerol esters, polyglycerol esters, fluorine-based compounds and combinations thereof, wherein the additive has a Hydrophile-Lipophile Balance value in the range of from 7 to 18; and iii) an inorganic filler; wherein the second layer is adjacent to the first layer and c) a skin layer comprising a polyolefin component, is disclosed. The multi-layer film is used in greenhouse applications.

Abstract: Embodiments of films, for example, infrared absorbing, heat retaining films, comprise at least one polymer selected from: a low density polyethylene (LDPE) having a density range of 0.900 g/cc to 0.930 g/cc and a melt index (I2) of 0.3 g/10 min to 2.0 g/10 min as measured in accordance with ASTM D1238; a linear low density polyethylene (LLDPE) having a density range of 0.900 g/cc to 0.930 g/cc and a melt index I2 of 0.3 g/10 min to 2.0 g/10 min; and a ethylene vinyl acetate copolymer having a vinyl acetate content ranging from 3 wt. % to 27 wt. % and a melt index I2 of 0.2 g/10 min to 10 g/10 min. The films also comprise a hybrid filler comprising (i) a layered double hydroxide, and (ii) an inorganic powder complex having a particle size distribution defined by a median diameter (D50) of 1.5 to 20 ?m.

Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.

Abstract: Analyzing software change impact is provided. Feedback is received regarding a predicted impact of a software change to a set of components of a service. It is determined whether the predicted impact of the software change is correct based on the feedback. In response to determining that the predicted impact of the software change is correct based on the feedback, the software change is applied to the set of components of the service increasing performance of the service and a server computer hosting the service.

Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone.

Abstract: The present invention relates to a process for producing leather in which methanesulfonic acid (MSA) is used in the pickling step at a high pH value, and the use of MSA is to improve the quality of the final leather product as well as to improve the environmental impact of the waste liquor.

Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: A child transportation system is disclosed. The system includes a seating component and various other modules. The system can check whether a seating component is located in a vehicle, whether the seating component is a proper component given the weight and height of the child in the seat, that the seating component is properly secured in the vehicle, and that the system is operating correctly. The system can monitor various conditions of the seat and the environment, and can provide alarms to users when cheks are not completed or dangerous environmental conditions are present, or when a child is left behind in a vehicle.

Abstract: Cognitively detecting cloud services and their associated status of a Virtual Machine and/or Container in a cloud platform to predict availability of cloud services preferably including the status of the services, a service object health map, and a service health status. The outputs are preferably sent to a user for feedback, which is sent back to the cognitive service.

Abstract: A method for event identification including receiving event information pertaining to events occurring with respect to a computing environment, each event having a measurement metric; evaluating by a probability function the measurement metric for each event to determine when the measurement metric is above a predetermined probability threshold or below a probability threshold wherein above a probability threshold or below a probability threshold is classified as alarm data; processing the alarm data through a decision tree to determine based on historical data when the alarm data is significant or when the alarm data is not significant and to reduce the number of alarm data to a predetermined number of significant alarm data; and displaying the predetermined number of significant alarm data to a user.

Abstract: An approach is provided for orchestrating computing resources between different computing environments. Data from first and second computing environments is monitored. The data specifies utilization of infrastructure, middleware, software testing tools, integrated development environments (IDEs), relationships among nodes, utilization of the nodes, and user behavior in the first and second computing environments. Based on the utilization of the infrastructure, middleware, tools, IDEs, node relationships and utilization, and user behavior, a pattern decision tree is updated, and unbalanced workloads are identified. Based on a comparison of the unbalanced workloads to patterns in the updated pattern decision tree, an orchestration topology is generated that specifies a new placement of the computing resources in the first and second computing environments.

Abstract: Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract: An approach is provided for orchestrating computing resources between different computing environments. Data from first and second computing environments is monitored. The data specifies utilization of infrastructure, middleware, software testing tools, integrated development environments (IDEs), relationships among nodes, utilization of the nodes, and user behavior in the first and second computing environments. Based on the utilization of the infrastructure, middleware, tools, IDEs, node relationships and utilization, and user behavior, a pattern decision tree is updated. Based on the updated pattern decision tree and a user request that specifies requirements of the computing resources, an orchestration topology is generated that specifies a placement of the computing resources in the first and second computing environments.

Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, for use as a human PDE1 inhibitor.